Full Text View
Tabular View
No Study Results Posted
Related Studies
Second Line Erlotinib (Tarceva) Plus Digoxin in Non-Small Cell Lung Cancer
This study is currently recruiting participants.
Study NCT00281021   Information provided by James Graham Brown Cancer Center
First Received: January 23, 2006   Last Updated: September 10, 2008   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Carcinoma, Non-Small Cell Lung
Additional conditions recognized in this trial
Carcinoma
Carcinoma, Non-Small-Cell Lung
Lung Neoplasms
More general conditions related to this trial
Lung Diseases
Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Glandular and Epithelial
Respiratory Tract Diseases
Respiratory Tract Neoplasms
Thoracic Neoplasms
Interventions listed in this trial
Erlotinib plus Digoxin
Additional drug interventions recognized in this trial
Digoxin
Erlotinib
More general drug interventions related to this trial
Anti-Arrhythmia Agents
Cardiotonic Agents
Cardiovascular Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Protective Agents
Protein Kinase Inhibitors
Therapeutic Uses
Sponsors listed in this trial
James Graham Brown Cancer Center
University of Louisville


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services